Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.

Marchesi F, Salvatorelli E, Renzi D, Mengarelli A, Minotti G, Menna P.

Br J Haematol. 2019 Oct;187(1):e15-e17. doi: 10.1111/bjh.16132. Epub 2019 Aug 1. No abstract available.

PMID:
31368155
2.

Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.

Minotti G, Menna P, Calabrese V, Greco C, Armento G, Annibali O, Marchesi F, Salvatorelli E, Reggiardo G.

J Pharmacol Exp Ther. 2019 Aug;370(2):197-205. doi: 10.1124/jpet.119.258178. Epub 2019 May 17.

PMID:
31101682
3.

Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.

Menna P, Minotti G, Salvatorelli E.

Curr Cardiol Rep. 2019 Apr 15;21(5):40. doi: 10.1007/s11886-019-1131-y.

PMID:
30989376
4.

Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.

Menna P, Minotti G, Salvatorelli E.

Curr Cardiol Rep. 2019 Mar 18;21(5):33. doi: 10.1007/s11886-019-1121-0. Review. Erratum in: Curr Cardiol Rep. 2019 Apr 15;21(5):40.

PMID:
30887161
5.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018;63(5):253-256. doi: 10.1159/000494329. Epub 2018 Nov 20.

PMID:
30458443
6.

The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.

Menna P, Salvatorelli E, Armento G, Annibali O, Greco C, Marchesi F, Calabrese V, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Dec;367(3):518-527. doi: 10.1124/jpet.118.253104. Epub 2018 Oct 1.

PMID:
30275150
7.

Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E, Marchesi F, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Jul;366(1):158-168. doi: 10.1124/jpet.118.249235. Epub 2018 May 2.

PMID:
29720563
8.

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.

Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.

9.

Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2018 Feb;364(2):323-331. doi: 10.1124/jpet.117.246140. Epub 2017 Dec 8.

PMID:
29222131
10.

Cancer drugs and QT prolongation: weighing risk against benefit.

Menna P, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20. No abstract available.

PMID:
28699784
11.

Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2017 Aug;362(2):263-270. doi: 10.1124/jpet.117.242388. Epub 2017 May 30.

PMID:
28559479
12.

Do You Know Pixantrone?

Minotti G, Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):192-193. doi: 10.1159/000464276. Epub 2017 Mar 24. No abstract available.

13.

Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.

Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):159-168. doi: 10.1159/000455823. Epub 2017 Jan 26.

14.

Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.

Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Arcese W, Mengarelli A; Rome Transplant Network.

Chemotherapy. 2017;62(1):58-61. Epub 2016 Sep 10.

15.

Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2016 Aug 15;29(8):1270-8. doi: 10.1021/acs.chemrestox.6b00190. Epub 2016 Jul 22.

PMID:
27420111
16.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

17.

The concomitant management of cancer therapy and cardiac therapy.

Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, Minotti G.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2727-37. doi: 10.1016/j.bbamem.2015.01.003. Epub 2015 Jan 14. Review.

18.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.

Menna P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, Galati G, Minotti G, Picardi A.

J Viral Hepat. 2014 Oct;21(10):e136-7. doi: 10.1111/jvh.12264. Epub 2014 Jun 16. No abstract available.

PMID:
24935352
19.

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Cacciapaglia F, Salvatorelli E, Minotti G, Afeltra A, Menna P.

Cardiovasc Toxicol. 2014 Dec;14(4):387-92. doi: 10.1007/s12012-014-9257-z.

PMID:
24798036
20.

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.

J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.

PMID:
23192654
21.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

PMID:
22972909
22.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):474-83. doi: 10.1124/jpet.111.190264. Epub 2012 Feb 15.

PMID:
22338034
23.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.

Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):464-73. doi: 10.1124/jpet.111.190256. Epub 2012 Feb 15.

PMID:
22338033
24.

Anthracycline cardiotoxicity.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36. doi: 10.1517/14740338.2011.589834. Epub 2011 Jun 2. Review.

PMID:
21635149
25.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466
26.

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A.

Autoimmun Rev. 2011 Aug;10(10):631-5. doi: 10.1016/j.autrev.2011.04.014. Epub 2011 Apr 22. Review.

PMID:
21539939
27.

Pharmacological foundations of cardio-oncology.

Minotti G, Salvatorelli E, Menna P.

J Pharmacol Exp Ther. 2010 Jul;334(1):2-8. doi: 10.1124/jpet.110.165860. Epub 2010 Mar 24.

PMID:
20335321
28.

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2010 Jan;23(1):6-10. doi: 10.1021/tx9003424.

PMID:
19954191
29.

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p.

PMID:
19397277
30.

Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.

Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14.

PMID:
19144686
31.

Cardiotoxicity of antitumor drugs.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2008 May;21(5):978-89. doi: 10.1021/tx800002r. Epub 2008 Apr 1.

PMID:
18376852
32.

Anthracycline cardiotoxicity.

Menna P, Salvatorelli E, Gianni L, Minotti G.

Top Curr Chem. 2008;283:21-44. doi: 10.1007/128_2007_11.

PMID:
23605627
33.

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.

Gianni L, Salvatorelli E, Minotti G.

Cardiovasc Toxicol. 2007;7(2):67-71. Review.

PMID:
17652806
34.

Doxorubicin degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

J Pharmacol Exp Ther. 2007 Jul;322(1):408-19. Epub 2007 Apr 27.

PMID:
17468298
35.

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2007 Feb;320(2):790-800. Epub 2006 Nov 29.

PMID:
17135345
36.

In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.

Menna P, Minotti G, Salvatorelli E.

Cell Biol Toxicol. 2007 Jan;23(1):49-62. Epub 2006 Oct 9. Review.

PMID:
17031515
37.

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2006 Jul;318(1):424-33. Epub 2006 Apr 13.

PMID:
16614166
38.

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, Minotti G.

J Biol Chem. 2006 Apr 21;281(16):10990-1001. Epub 2006 Jan 19.

39.

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L.

Pharmacol Rev. 2004 Jun;56(2):185-229. Review.

PMID:
15169927
40.

Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.

Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G.

Methods Enzymol. 2004;378:340-61. Review. No abstract available.

PMID:
15038979
41.

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L.

Eur J Cancer. 2004 Mar;40(4):563-70.

PMID:
14962724
42.

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P, Minotti G.

J Biol Chem. 2004 Feb 13;279(7):5088-99. Epub 2003 Nov 21.

43.

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, Minotti G.

Br J Pharmacol. 2003 Jun;139(3):641-51.

44.

Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.

Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM, Minotti G.

Chem Res Toxicol. 2002 Sep;15(9):1179-89.

PMID:
12230412
46.

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

Minotti G, Parlani M, Salvatorelli E, Menna P, Cipollone A, Animati F, Maggi CA, Manzini S.

Br J Pharmacol. 2001 Nov;134(6):1271-8.

Supplemental Content

Loading ...
Support Center